Triton Reference Database
Launched by TOPCON CORPORATION · Feb 24, 2017
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
The objective of this study is to collect OCT measurement data on normal healthy eyes in order to determine the reference limits for Topcon DRI OCT Triton based on the percentile points for 1%, 5%, 95%, and 99%.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • 1. Subjects 18 years of age or older on the date of informed consent
- • 2. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
- • 3. Subjects presenting at the site with normal eyes bilaterally (cataracts are acceptable)
- • 4. IOP ≤ 21 mmHg bilaterally
- • 5. BCVA 20/40 or better bilaterally
- • Exclusion Criteria
- • 1. Subjects unable to tolerate ophthalmic imaging
- • 2. Subjects with ocular media not sufficiently clear to obtain acceptable OCT images
- • 3. HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on manufacturer's recommendation), defined as fixation losses \> 20% or false positives \> 33%, or false negatives \> 33%
- 4. Visual field defects consistent with glaucomatous optic nerve damage based on at least one of the following two findings:
- • 1. On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level;
- • 2. Glaucoma hemi-field test "outside normal limits."
- • 5. Narrow angle
- • 6. History of leukemia, dementia or multiple sclerosis
- • 7. Concomitant use of hydroxychloroquine and chloroquine
About Topcon Corporation
Topcon Corporation is a global leader in precision measurement and imaging solutions, specializing in the fields of ophthalmology, optometry, and geospatial technology. With a commitment to advancing healthcare through innovative technologies, Topcon develops cutting-edge diagnostic equipment and software that enhance clinical decision-making and improve patient outcomes. The company actively sponsors clinical trials aimed at evaluating the efficacy and safety of its products, contributing to the advancement of eye care and vision science. Through collaboration with healthcare professionals and research institutions, Topcon continues to drive innovation and support the development of evidence-based practices in the medical field.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Jamaica, New York, United States
Chicago, Illinois, United States
Anaheim, California, United States
Pasadena, California, United States
Willmar, Minnesota, United States
Patients applied
Trial Officials
Charles Riesman, MS
Study Chair
Topcon Corporation
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials